SPOTLIGHT -
Slideshow
Author(s):
There are a few things that we all agree on, as reflected in a recent consensus statement.
Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score
Not All That Writhes Is Tardive Dyskinesia
New 48-Week Remission Data on Ingrezza for the Treatment of Tardive Dyskinesia
Phase 1 Study Initiated: NBI-1140675 for Neurological and Neuropsychiatric Conditions
Significant Improvements in Functionality and Quality of Life: New Data on Ingrezza for Tardive Dyskinesia
Psychopharmacology Innovations